ACADIA Pharmaceuticals Inc.
ACAD
$16.12
-$0.50-3.01%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.36% | 18.28% | 46.44% | 73.75% | 69.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.36% | 18.28% | 46.44% | 73.75% | 69.27% |
| Cost of Revenue | 44.78% | -50.19% | 42.63% | 16.69% | 8.29% |
| Gross Profit | -6.38% | 311.17% | 48.98% | 158.55% | 150.96% |
| SG&A Expenses | 16.70% | 20.95% | 21.98% | 6.67% | 6.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.82% | -24.35% | 30.41% | 10.80% | 7.42% |
| Operating Income | -80.00% | 180.56% | 902.21% | 128.39% | 175.86% |
| Income Before Tax | 305.73% | 174.42% | 486.19% | 146.73% | 197.10% |
| Income Tax Expenses | 384.59% | -53.65% | -27.46% | 331.86% | -829.82% |
| Earnings from Continuing Operations | 213.87% | 150.27% | 2,897.22% | 138.48% | 209.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 213.87% | 150.27% | 2,897.22% | 138.48% | 209.76% |
| EBIT | -80.00% | 180.56% | 902.21% | 128.39% | 175.86% |
| EBITDA | -66.64% | 187.62% | 587.24% | 139.01% | 180.27% |
| EPS Basic | 210.58% | 149.75% | 2,866.18% | 137.91% | 207.88% |
| Normalized Basic EPS | -58.31% | 201.92% | 477.78% | 146.04% | 176.55% |
| EPS Diluted | 213.27% | 149.35% | 2,841.18% | 137.04% | 204.74% |
| Normalized Diluted EPS | -57.94% | 201.81% | 482.50% | 145.52% | 175.73% |
| Average Basic Shares Outstanding | 1.05% | 1.06% | 1.28% | 1.56% | 1.74% |
| Average Diluted Shares Outstanding | 0.11% | 1.18% | 0.68% | 2.69% | 2.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
